Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Recap by typeshit. Full story at Medical Daily.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
A Dongguk University family medicine professor calls gallbladder risk the real concern and says some Koreans fly to Japan, where the drugs reportedly cost about a third.
He says GLP-1s help people with obesity, but taking tirzepatide just to get lean brought him dizziness, low intake and declining gym performance.
Loading…